Molecular Assemblies Closes Oversubscribed $24 Million Series A Financing To Advance Enzymatic Dna Synthesis Toward Initial Commercial Access
Molecular Assemblies Closes Oversubscribed $24 Million Series A Financing To Advance Enzymatic Dna Synthesis Toward Initial Commercial Access
04/15/21, 11:11 AM
Location
san diegoMoney raised
$24 million
Round Type
series a
Molecular Assemblies, Inc., today announced that it has closed an oversubscribed $24 million Series A financing with significant investment from Agilent Technologies, iSelect Fund, Codexis, Alexandria Venture Investments, and Argonautic Ventures. In addition LYFE Capital has joined the syndicate. The proceeds of the financing will be used to advance the company's proprietary enzymatic DNA synthesis technology toward early commercialization efforts.
Company Info
Location
san diego, california, united states
Additional Info
Molecular Assemblies, Inc. is a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company's patented enzymatic method, based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably, and sustainably. Molecular Assemblies' technology will enable the reading and writing of DNA for many industries, including industrial synthetic biology and precision medicine, as well as emerging applications of DNA for data information storage, nanomachines, and bio-based electronics. Molecular Assemblies is headquartered in San Diego. For more information, please visit www.molecularassemblies.com.